 |
DAEJEON, South Korea, Feb. 25, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the completion of last patient last visit in its Phase Ib combination trial for mTNBC (metastatic Triple-Negative Breast Cancer)...
A few weeks ago, I was watching the Super Bowl. Traditionally, those halftime ad spots are reserved for the world’s biggest, most established bran...
Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience ...
We spend millions designing features that save users 30 seconds. Block just saved thousands of employees 40 hours a week. That's not a crisis. That's...
Why does building a home still feel like stepping into the unknown? In an industry where costs blow out and decisions come too late, certainty has...
The company has also launched its developer API to empower creators and builders to integrate AI into their workflows SYDNEY, Australia – 19 Febr...
Psychological injury is now one of the most expensive categories of workers compensation claims in Australia, with Safe Work Australia reporting t...